Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kalos

Showing results (231-240 of 236) with videos related to

Pageof 24
Sort By:
You have reached the last page of results.This site can display upto 236 results.
Science Translational Medicine|August 9, 2013
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cellsBrian J Cameron, Andrew B Gerry, Joseph Dukes, et al.
Frontiers in Immunology|December 3, 2025
Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphomaLilit Karapetyan, Joel Kuriakose, Matthew C Perez, et al.
Transplantation and Cellular Therapy|December 20, 2025
Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patientsLilit Karapetyan, Joel Kuriakose, Elizabeth DiMaggio, et al.
Nature Medicine|May 8, 2012
Monoclonal TCR-redirected tumor cell killingNathaniel Liddy, Giovanna Bossi, Katherine J Adams, et al.
Nature Medicine|July 21, 2015
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myelomaAaron P Rapoport, Edward A Stadtmauer, Gwendolyn K Binder-Scholl, et al.
Nature|June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsJoseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.
Pageof 24

Showing results (231-240 of 236) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 236 results.
Science Translational Medicine|August 9, 2013
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cellsBrian J Cameron, Andrew B Gerry, Joseph Dukes, et al.
Frontiers in Immunology|December 3, 2025
Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphomaLilit Karapetyan, Joel Kuriakose, Matthew C Perez, et al.
Transplantation and Cellular Therapy|December 20, 2025
Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patientsLilit Karapetyan, Joel Kuriakose, Elizabeth DiMaggio, et al.
Nature Medicine|May 8, 2012
Monoclonal TCR-redirected tumor cell killingNathaniel Liddy, Giovanna Bossi, Katherine J Adams, et al.
Nature Medicine|July 21, 2015
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myelomaAaron P Rapoport, Edward A Stadtmauer, Gwendolyn K Binder-Scholl, et al.
Nature|June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsJoseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.
Pageof 24